Sarcopenia

Decoding Sarcopenia: Advances in Research and Management: Dive into the evolving landscape of sarcopenia research. From cutting-edge studies on its impact on cancer patients to innovative management strategies, gain insights into combating this muscle-wasting condition.

Artificial intelligence analysis of temporalis muscle thickness for monitoring sarcopenia and clinical outcomes in individuals with paediatric brain tumours: a retrospective cohort study.

BACKGROUND

People with and who have survived paediatric brain tumour (PBT) have a poor quality of life due to physiological frailty, a primary component of which is sarcopenia (ie, low lean muscle mass) and the associated condition, sarcopenic overweight. MRI-based temporalis...

🗓️ 2026-05-28
Read MoreArtificial intelligence analysis of temporalis muscle thickness for monitoring sarcopenia and clinical outcomes in individuals with paediatric brain tumours: a retrospective cohort study.

Sarcopenia in Diabetes: A proposal on integrating muscle assessment and nutritional intervention in people living with diabetes.

Sarcopenia is a progressive muscle disease characterized by loss of skeletal muscle mass and strength, commonly associated with ageing and chronic diseases. Type 2 diabetes mellitus (T2DM) accelerates its development through insulin resistance, chronic inflammation, oxidative stress, and hyperglycaemia. Sarcopenia...

🗓️ 2026-05-27
📰 Publication: Diabetes Research And Clinical Practice
Read MoreSarcopenia in Diabetes: A proposal on integrating muscle assessment and nutritional intervention in people living with diabetes.

Exploring the role of parathyroid hormone in sarcopenia: A review.

PURPOSE OF REVIEW

Sarcopenia is a progressive, multifactorial geriatric syndrome linked to increased risk of falls, fractures, disability, frailty, and all-cause mortality. The pathophysiology of this complex syndrome remains unclear. Emerging evidence suggests that chronically elevated parathyroid hormone (PTH) concentration may...

🗓️ 2026-05-27
Read MoreExploring the role of parathyroid hormone in sarcopenia: A review.

Circulating biomarkers in older adults with and without sarcopenia: a systematic review and meta-analysis.

BACKGROUND

Sarcopenia, the age-related loss of muscle mass and strength, poses a significant health and economic burden. This systematic review and meta-analysis evaluates circulating biomarkers (activin A, follistatin, growth differentiation factor (GDF-15), myostatin, growth hormone, insulin growth factor-1 (IGF-1), free and...

🗓️ 2026-05-27
📰 Publication: Journals Of Gerontology Series A-Biological Sciences And Medical Sciences
Read MoreCirculating biomarkers in older adults with and without sarcopenia: a systematic review and meta-analysis.

The Gut-Muscle Axis in Sarcopenia: Mechanisms, Evidence Gaps and Translational Challenges.

Sarcopenia is an age-related skeletal muscle disorder characterized by reduced muscle mass, strength, and physical performance, as well as increased risk of disability, hospitalization, and mortality. Emerging evidence suggests that gut microbiota alterations may contribute to muscle decline via a...

🗓️ 2026-05-27
Read MoreThe Gut-Muscle Axis in Sarcopenia: Mechanisms, Evidence Gaps and Translational Challenges.

Ginsenoside Ro ameliorates d-galactose-induced sarcopenia by modulating oxidative stress, inflammation, and gut microbiota in mice.

BACKGROUND

Sarcopenia is an age-related disorder primarily characterized by progressive muscle degeneration, and effective therapeutic interventions for this condition remain limited. Ginsenoside Ro (GRo) exhibits antioxidant and anti-inflammatory effects. However, the impact of GRo on skeletal muscle aging, myoblast differentiation, and...

🗓️ 2026-05-22
📰 Publication: Phytomedicine
Read MoreGinsenoside Ro ameliorates d-galactose-induced sarcopenia by modulating oxidative stress, inflammation, and gut microbiota in mice.

Body Composition Changes in Patients on GLP-1 Receptor Agonists Undergoing an Intensive Cardiac Rehabilitation Program.

BACKGROUND

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for type 2 diabetes and obesity and produce significant weight loss. However, concerns have emerged about potential loss of skeletal muscle mass (SMM) with pharmacologic weight reduction, particularly in older adults...

🗓️ 2026-05-21
📰 Publication: European Journal Of Preventive Cardiology
Read MoreBody Composition Changes in Patients on GLP-1 Receptor Agonists Undergoing an Intensive Cardiac Rehabilitation Program.

Why Osteosarcopenia Matters: Clinical and Investigative Implications.

BACKGROUND

Osteosarcopenia, the combination of osteoporosis and sarcopenia, is a geriatric syndrome linked to functional decline, falls, and fragility fractures. The interaction among bone, muscle, and their shared pathophysiology is driven by mechanical, metabolic, and hormonal factors. With global population aging...

🗓️ 2026-05-15
📰 Publication: European Journal Of Clinical Investigation
Read MoreWhy Osteosarcopenia Matters: Clinical and Investigative Implications.

A narrative review of sarcopenia in patients with cardiovascular kidney metabolic syndrome: Another brick in the wall?

Cardiovascular-kidney-metabolic syndrome (CKMS) is a recently launched by American Heart Association to express the importance of interplay among metabolic risk factors, chronic kidney disease, and the cardiovascular system which has profound impacts on morbidity and mortality. The common pathologic processes...

🗓️ 2026-05-13
📰 Publication: Clinical Nutrition
Read MoreA narrative review of sarcopenia in patients with cardiovascular kidney metabolic syndrome: Another brick in the wall?

Discovery of a Potent Antisarcopenia Drug Molecular Scaffold Derived from Ligusticum chuanxiong and Its Photochemical Synthesis.

Sarcopenia is a growing public health crisis with an unmet need for effective pharmacotherapies. Ligusticum chuanxiong (L. chuanxiong), commonly known as Chuanxiong in China, is a medicinal plant widely utilized for conditions involving muscle wasting and weakness. Herein, we report...

🗓️ 2026-05-11
📰 Publication: Journal Of The American Chemical Society
Read MoreDiscovery of a Potent Antisarcopenia Drug Molecular Scaffold Derived from Ligusticum chuanxiong and Its Photochemical Synthesis.

The diagnostic accuracy of blood biomarkers for sarcopenia, sarcopenic obesity, and osteosarcopenia: a meta-analysis.

BACKGROUND AND AIMS

Sarcopenia is the accelerated loss of skeletal muscle mass and function associated with ageing. Sarcopenia screening consists of body composition imaging and physical function tests; however, these tests can be burdensome and inconsistent. This review aimed to synthesise...

🗓️ 2026-05-11
📰 Publication: Archives Of Gerontology And Geriatrics
Read MoreThe diagnostic accuracy of blood biomarkers for sarcopenia, sarcopenic obesity, and osteosarcopenia: a meta-analysis.

Beyond the Lungs: The Role of Extrapulmonary Manifestations in the Quality of Life of Indians with Chronic Airway Diseases.

PURPOSE

Chronic airway diseases (CAD) including Chronic obstructive pulmonary diseases (COPD), persistent asthma (≥2weekly episodes) and bronchiectasis, exhibit overlapping extrapulmonary manifestations potentially affecting health-related quality-of-life (HRQOL). The study objective was to quantify HRQOL of CAD patients and identify impact of associated...

🗓️ 2026-05-09
📰 Publication: Respiratory Medicine
Read MoreBeyond the Lungs: The Role of Extrapulmonary Manifestations in the Quality of Life of Indians with Chronic Airway Diseases.

Sarcopenia, Grip Strength, Walking Pace, and New-Onset Stroke Risk: A UK Biobank Study.

BACKGROUND

Novel stroke risk factors have received widespread attention. This study examined the association between sarcopenia status, grip strength, and walking pace with incident stroke (any stroke, ischemic stroke, and hemorrhagic stroke) and poststroke mortality.

METHODS

This prospective study included 482 699 participants from...

🗓️ 2026-05-08
📰 Publication: Stroke
Read MoreSarcopenia, Grip Strength, Walking Pace, and New-Onset Stroke Risk: A UK Biobank Study.

The Association of Sarcopenic Obesity With Respiratory Function Outcomes in Adults: A Systematic Review and Meta-Analysis.

Sarcopenic obesity has been associated with various health conditions and mortality. Our objective was to systematically review and estimate the association between sarcopenic obesity and respiratory function outcomes. We searched EMBASE, MEDLINE, and Google Scholar for observational studies involving adults...

🗓️ 2026-05-08
📰 Publication: Obesity Reviews
Read MoreThe Association of Sarcopenic Obesity With Respiratory Function Outcomes in Adults: A Systematic Review and Meta-Analysis.

SARCOPENIA DEFINITION

Sarcopenia is a condition which focuses on muscle loss. Loss of muscle mass and function, especially muscle strength and gait speed, associated with aging occurs in sarcopenia. Sarcopenia, cachexia, and malnutrition are considered as the main causes of muscle wasting and affect millions of elderly people and patients. Moreover, muscle atrophy can develop independently from diseases and age through disuse of the muscles. For a better classification and common language in medical science for ‘muscle wasting disease’ there is a proposal to combine the concepts of muscle wasting, sarcopenia, frailty, and cachexia by disease aetiology and disease progression. Patients with muscle atrophy show decreased muscle strength and therefore reduced quality of life, which is caused by a lower activity and increased exercise intolerance.

Despite a large number of studies, the understanding of the development of muscle wasting and the involved pathways remains very limited and more research is needed. Although many researchers and pharmaceutical companies have tried to find therapies for muscle atrophy, including cachexia and sarcopenia, no solution has been established until now.

REFERENCES

Rosenberg IH. Sarcopenia: origins and clinical relevance. Clin Geriatr Med 2011;27:337–339.

Anker SD, Coats AJ, Morley JE, Rosano G, Bernabei R, von Haehling S, Kalantar-Zadeh K. Muscle wasting disease: a proposal for a new disease classification. J Cachexia Sarcopenia Muscle 2014;5:1–3

Subscribe to the SCWD Newsletter

Stay Informed with the Latest Updates and Exclusive Insights!